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The question of whether and how changes to population health impact on economic growth
has been actively studied in the literature, albeit with mixed results. We contribute to this
debate by reassessing–and extending–[1], one of the most influential studies. We include a
larger set of countries (135) and cover a more recent period (1990–2014). We also account
for morbidity in addition to mortality and adopt the strategy of providing bounding sets for the
effects of interest rather than point estimates. We find that reducing mortality and disability
adjusted life years (DALYs), a measure which combines morbidity and mortality, promotes
per capita GDP growth. The magnitude of the effect is moderate, but non negligible, and it is
similar for mortality and DALYs.
1. Introduction
Since the end of World War II mortality rates have been decreasing and life expectancy has
been increasing all over the world, with the notable exceptions of the Former Soviet Union
during the transition from communism, and Southern Africa during the HIV-AIDS epidemic.
However, the extent to which the observed health improvement has played a causal role in pro-
moting the similarly favorable economic development worldwide over the same period
remains theoretically ambiguous.
On the one hand, better health may improve economic performance: lower mortality and
longer lives would be expected to favor investments in physical and human capital, which in
turn are major engines of sustained growth [2,3]. On the other hand, a fall in mortality rates, if
not accompanied or preceded by a corresponding fertility decline, accelerates population
growth and may lead to lower production per capita [4]. Therefore, quantifying the effect of
changes in mortality on economic growth is crucial to helping governments formulate policy
to promote or counteract these effects.
A considerable literature has studied the effects of mortality or life expectancy on economic
performance. Early studies generally found a strong positive association between health and
economic performance, defined as either the growth or level of GDP per capita. More recently,
the literature has recognized that this result may be caused by omitted or poorly controlled
country characteristics: factors that support or slow down economic development might also
be responsible for a country’s population health. For instance, good political and economic
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institutions may have triggered both sustained economic growth and improved population
health by reducing within-country inequalities [5].
The recent empirical evidence on the subject is mixed, as exemplified by the contrasting
results of two seminal papers, [4] (Acemoglu and Johnson—AJ) and [1] (Lorentzen, McMillan,
andWacziarg—LMW). While AJ find a negative effect of health on economic performance,
LMW find a positive one despite the fact that both studiesuse broadly comparable specifica-
tions. AJ exploit the longitudinal nature of a panel of low and middle-income countries (LMIC)
between 1940 and 1980 and set up a first-difference model where differenced GDP per capita is
regressed on differenced life expectancy (their proxy of health). They find that improvements to
life expectancy have a significant negative effect on GDP per-capita. LMW define a cross-sec-
tional growth regression model and regress differenced GDP per capita on the initial level of
GDP per capita and health. They consider adult and infant mortality rates as iesproxies of poor
health in a global sample of over 80 countries between 1960 and 2000 and find a strong signifi-
cant negative effect of both adult and infant mortality on per-capita GDP growth.
Subsequent papers tried to reconcile the AJ and LMW results. Particularly, [6] reconsidered
the AJ analysis, and by separating the sample into pre- and post-demographic transition coun-
tries, it was able to replicate the AJ findings of negative growth impacts only for the former
group of countries (characterized by high mortality, high fertility and increasing population
growth). More recently, [7] indirectly confirmed this result, finding a positive effect of life
expectancy both on GDP and GDP growth on a small sample of post-demographic transition
countries.
Complementing [6], in this paper we reconsider LMW analysis and we extend it along sev-
eral dimensions. First, we use more extensive and more recent data studying the impact of mor-
tality rates on long-run GDP per-capita growth in a sample of 135 countries between 1990 and
2014. Second, we assess the impact of disability-adjusted life years (DALYs) per capita (a com-
bined measure of morbidity and mortality) in the working age population, besides population
mortality: this helps us to assess the long-term impact on human capital and productivity. Third
and more importantly, methodologically we take a different stand compared to the literature.
We aim to provide bounding sets for the effect of population health on economic growth, to
give the reader a range of plausible estimates rather than a unique value. This is because we
share the concern for the endogeneity problems which are responsible for possibly large bias in
the estimates and threaten the causal interpretation of the findings. Particularly concerning is
the validity of the instrumental variables (IV) used in the literature. The predicted mortality
instrument used in AJ has been criticized by [8] and [9], both on the grounds of its relevance
and of its validity. Similarly, the battery of geographical, climatic and epidemiological condi-
tions exploited by LMW raises aa concern that these are structural characteristics which shaped
a country’s economy, its culture and social organization, and not only population mortality.
Lacking better alternatives and withstanding the importance of answering the question of
whether population health is a lever of economic growth, we take the more prudent approach of
providing credible bounding sets for the effects of interest, rather than point estimates.
We first assess to what extent the omitted variable bias drives the association between GDP
per capita growth and mortality, by applying the strategy suggested by [10]. We find that if
some variables were omitted from the model, the estimated effect of mortality and morbidity
on GDP per capita would actually be larger in absolute value. We put under scrutiny this “opti-
mistic” conclusion by performing an IV analysis, where we instrument mortality (resp.
DALYs) by the proportion of a country’s inhabitants exposed to the Plasmodium Falciparum
in 1966. This is a (pre-determined) contributor of Sachs’ Malaria Ecology Index that was part
of the original LMW set of instrumental variables which is, we argue, the least criticizable
among the instruments in LMW.
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Contrary to geographical and climatic conditions which are persistent in the long run and
likely shape a country development path, the spread of malaria varied over time quite substan-
tially, and its diffusion in 1966 only partially corresponds to its spread during our study period
and to its diffusion in ancient times. Accordingly, the concern that malaria determines the evo-
lution of a country economy, as geographic and climate variables can do, is less compelling.
Historically, malaria was common in the US, Europe and Russia. For instance, poet Friedrich
Schiller contracted the disease in Germany, Oliver Cromwell in Ireland, and Abraham Lincoln
in Illinois [11]. In Italy, Spain and Northern Australia malaria was prevalent in the low lands
until the Fifties and the Sixties respectively. The marked variation of malaria prevalence over-
time is also apparent from its death toll, which reached its peak around 2005 to over 800k
deaths per year and thereafter declined by more than one quarter. Malaria diffusion responds
to the implementation of public health measures, especially the widespread use of insecticides,
the drainage of swampland for expanding agricultural land, accessibility to treatments and
improvements in housing conditions. In the tropical and sub-tropical areas, in Africa, South-
ern Asia and Central and Latin America, malaria is still endemic but on retreat. Also, the
spread of malaria varies within countries, low and humid lands being more prone than others.
Both rich and poor countries today, were in the past affected by malaria, nonetheless we
cannot rule out the possibility that malaria is correlated with a country’s economic perfor-
mance throughout mechanisms other than its population health or mortality. For instance,
malaria can slow down the economic development of low and humid areas, and force the pop-
ulation to concentrate on high lands, distant from rivers and other natural communication
routes. If so, our IV might fail to meet the exclusion restriction and produce biased estimates.
To address this concern, we adopt a battery of methods, most of which belong to the
domain of partial identification, including [12,13] and [14] to provide bounds and check how
robust are our estimates to the violation of IV assumptions. To the best of our knowledge this
is the first time such methods have been employed in this literature.
We confirm that both mortality and morbidity have a negative effect on GDP per capita
growth. The effect of reducing mortality by 10 percent is that of adding at least 9.6 percentage
points to GDP per capita growth over a period of about one quarter century, according to [13]
bounding strategy. These estimates are fully coherent with the bounds obtained under [10]
assumptions. The effect of an equivalent reduction in DALYs is comparable to that of mortal-
ity. According to [13] the effect of reducing morbidity by 10 percent is that of increasing long
run growth of at least 10.6 percentage points. Importantly, our IV estimates are robust to [12]
and [14] stress tests.
We also find that the effects of mortality and morbidity are heterogenous across countries,
with the low and the high income countries displaying a stronger effect than the middle
income countries. Similarly, the effect varies non-linearly depending on the stage of the demo-
graphic transition at the beginning of the study period.
Finally, we illustrate the expected impact in monetary terms of reducing or increasing mor-
tality and morbidity in four selected countries, representing high income (the US), upper-mid-
dle income (China), lower-middle income (India) and low-income countries (Niger).
Specifically, we simulate the effect of marginally increasing or decreasing a country’s commit-
ment to health policies effective in reducing mortality and morbidity. We find non-negligible
benefits (costs) in strengthening (weakening) health policies, especially so in Niger and in the
US.
The rest of the paper is organized as follows. Section 2 briefly reviews the relevant literature.
Section 3 describes the data used. Section 4 introduces the methods adopted. Results are
reported in Section 5. The economic significance of our findings is discussed in Section 6 and
conclusions follow.
PLOS ONE Mortality, morbidity and economic growth
PLOSONE | https://doi.org/10.1371/journal.pone.0251424 May 27, 2021 3 / 22
2. Previous literature
Early studies generally found a strong positive association between population health and eco-
nomic growth. For instance, [15] reports that life expectancy is among the most robust predictors
of GDP per-capita growth. However, as [16] pointed out, much if not all of the early work on the
subject “suffer(s) from severe problems of endogeneity and omitted variable bias” ([16], p.1271).
The more recent literature explicitly acknowledges endogeneity problems and tries to
uncover the causal effect of health on GDP growth (see [3], for a review). Two seminal papers
have arguably renewed the interest in this question and have often been contrasted against one
another due to their contrasting conclusions. The first is AJ, which adopts an IV strategy cou-
pled with country fixed effects to analyze the influence of life expectancy on income levels. Its
identification strategy rests on the discovery of new chemicals and drugs to fight communica-
ble diseases. This IV approach combines the timing of discoveries with the country-specific
prevalence of the diseases that the new drugs are meant to treat. AJ covers 47 low and lower
middle-income countries for which data on total GDP, per-capita GDP and life expectancy are
available in 1940, 1980 and 2000. The results indicate that life expectancy has no significant
effect on total GDP level, a significantly positive effect on population size and, hence, a nega-
tive effect on per-capita GDP.
The second is LMW, which also uses an IV strategy, this time to analyze the effect of mor-
tality rates on per-capita GDP growth. Their sample covers 88 countries, and per-capita GDP
growth between 1960 and 2000 is regressed on the average adult and infant mortality rates reg-
istered between 1960 and 2000, the log of per-capita GDP in 1960, and several country con-
trols. Mortality rates are instrumented by the Malaria Ecology Index developed by [17] and a
battery of climatic variables and geographic characteristics. The results indicate a strong nega-
tive (i.e. health-improving) and significant effect of both adult and infant mortality rate on
per-capita GDP growth.
AJ and LMW address similar questions, both adopt IV identification strategies, and have
comparable model specifications. Unsurprisingly, the divergence in their findings has trig-
gered a substantial research effort in more recent years. [18] points out that the AJ model
omits the initial level of life expectancy. When the authors estimate a model similar to LMW,
but with per-capita income growth between 1960 and 2000 regressed on the change in life
expectancy in the period and its initial level, they find a positive contribution of both variables
on growth. A similar point has been raised by [9]. This paper also notes that controlling for ini-
tial life expectancy largely reduces the strength of AJ’s instrument, which is highly correlated
with mortality rates in the 1940s. Recently, [19] extends the AJ dataset by adding an observa-
tion relative to year 1900 for 35 of the original 47 countries. Hence two long term differences
for each country are computed, one between 1900 and 1940 and one between 1940 and 1980.
With two observations per country, country fixed effects can be included in the first-difference
model. Therefore, [19] accounts for the criticism raised by [9], that initial life expectancy was
omitted from the AJ model. Reassuringly, the results confirm and reinforce AJ conclusions.
[20] develops an estimation strategy akin to AJ’s to estimate the effect of life expectancy on
per-capita GDP across US states between 1940 and 1980. In line with AJ, the adopted instru-
ment is the interaction between mortality from 9 medically treatable communicable diseases
registered before discovering antibiotics and the date antibiotics were discovered. The advan-
tages of this within-country analysis are first, in the comparison of relatively homogenous eco-
nomic systems, and second, in the expected smaller measurement error due to the accurate
vital registration system established in America since 1933. The results show that increased life
expectancy has significant positive effects on population level and total GDP, while the effect
on GDP per capita is small and statistically insignificant.
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In an attempt to reconcile the AJ and LMW results, [6] replicate the AJ analysis on the
same data but distinguish between countries that, as of 1940, had already completed their
demographic transition towards a low fertility and low-mortality regime and countries that
had not. The key observation of [6] is that the introduction of new pharmaceuticals had the
immediate effect of reducing mortality, which was not immediately accompanied by a reduc-
tion in fertility. It follows that, at least for a certain period, population grew faster, causing a
fall in income per capita. The authors alternatively use the AJ and LMW instruments and, in
both cases, they find that increasing life expectancy causes an increase in GDP in post-transi-
tion countries while the effect is generally negative, though not always significantly different
from zero, among pre-transition countries. They conclude that the opposing results in AJ and
LMW are not due to the alternative instrumentation strategies, but rather to differences in the
samples of countries and time periods examined. In a later short paper [21], the same authors
further increase the degree of flexibility of their empirical analysis by defining a mixture model
that allows the data to determine whether any given country is to be considered pre- or post-
demographic transition rather than relying on an ex-ante classification.
From a perspective close to that of [6,22] notes that the response of GDP per capita to health
depends on what health dimension is considered. Whether health shocks mainly affect adults or
children makes a difference for the magnitude and the timing of the effects. In the former case the
effect is mainly through a variation in population size, while in the latter case it is mainly through
a variation in investments in human capital and indeed in the future supply of skilled labour.
An interesting source of exogenous variation has been exploited by [23]. They instrument
health (captured by mortality rates) by means of the progressive introduction of universal pub-
lic health care in 12 European countries between 1820 and 2010. Their findings indicate that
the introduction of public health systems led to significant reductions in infant mortality and
crude death rates that, in turn, had a significant positive effect on economic growth.
On the whole, the existing evidence appears to support the hypothesis of a positive effect of
longer life expectancy and lower mortality on economic growth. However, the existing work
tends to be limited to small samples of countries or focus on particular regions. Using larger
samples, as we do in this paper, allows us to achieve better global coverage and to harness the
empirical advantages of a larger sample size.
3. Data
The data used in this paper come from different sources. We consider population all-cause
mortality (per 100,000 inhabitants) and DALYs (per 100,000 inhabitants) in the working age
population (aged 15–64 years). DALYs are defined as the sum of years of potential life lost due
to premature mortality and the years of productive life lost due to disability. While DALYs in
the working age population mainly captures the influence of health on economic growth medi-
ated by labour supply and productivity, population mortality also accounts for the macroeco-
nomic effects of the survival rates in the elderly population, through savings, investment
decisions and social security expenditures, among others. Mortality and DALYs data are from
the Institute for Health Metrics and Evaluation (IHME) Global Health Data Exchange
(GHDx) GBD results tool. Mortality data are available annually for the timespan 1990 to 2015
while DALY information is only available every fifth year. In the appendix we replicate the
baseline analysis with mortality in the working-age population and DALYs in the whole popu-
lation, to assess the sensitivity of our findings to age-restrictions.
Data on malaria, and Köppen-Geiger climatic zones are from the Harvard University’s Cen-
ter for International Development (CID) database. We aggregate the original Köppen-Geiger
climatic zones in six indicators of the proportion of the country area in polar, boreal, humid
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temperate, dry temperate, subtropical and tropical zones. Version 9.0 of the PennWorld Tables
(PWT) provided data for real GDP as well as for government consumption, exports and
imports (in constant 2011 national prices using United States Dollars [USD]). TheWorld
Bank’s World Development Indicators (WDI) database provides data on population, the share
of population aged 65 and more, urbanization (% population living in urban agglomeration
greater than 1 million population) and internet penetration. The population share achieving at
least secondary education is obtained from the updated Barro-Lee (BL) world dataset (2012)
and a measure of social capital, namely the average level of generalized trust in the population,
is obtained from theWorld Values Survey (WVS). Finally, the 2002 version of the Freedom in
theWorld (FIW) database provided an index of political rights and civil liberties.
Overall, we have complete information for 135 countries. We compute the per-capita GDP
growth rate between 1990 and 2014 (in percentage points) and we average the remaining vari-
ables over the period 1990–2014, by country. Key descriptive statistics are reported in Table 1.
In the sample, income per capita increases on average by 63 percent from its 1990 level. Aver-
age mortality rate in the population is 896.14 per 100,000 inhabitants per year and the number
of healthy years lost for disability in the working age population is 18,630 per 100,000 inhabi-
tants on average.
4. Methods
To estimate the effect of mortality and morbidity on economic development we estimate a
long run growth regression model akin to LMW. A long-run growth model relates long-run
Table 1. Summary statistics. Variables Averaged over the period 1990–2014.
Variable Obs Mean Std. Dev. Min Max
Real GDPpc growth 1990–2014 (percent) 135 64.13 65.90 -43.68 441.96
All-cause DALYs (years per 100,000 inhab.) all ages 135 44.81 24.33 15.14 116.20
All-cause DALYs (years per 100,000 inhab.) 15–64 135 18.63 6.72 9.34 44.44
All-cause Mortality Rate (deaths per 100,000 inhab.) all ages 135 896.14 334.76 254.77 1812.25
All-cause Mortality Rate (deaths per 100,000 inhab.) 15–64 135 483.18 280.21 161.47 1407.69
FalciparumMalaria Index 1966 (% of resident population at risk) 135 32.65 42.47 0.00 100.00
log Real GDPpc 1990 135 8.72 1.19 5.90 11.70
Share of population aged 65 and over in 1990 135 6.36 4.22 1.20 17.82
OECD 1990 135 0.14 0.35 0.00 1.00
Log population 135 16.39 1.37 14.06 20.97
Urban (% of urban population) 135 54.33 22.11 8.82 100.00
Openness index 135 75.87 38.92 17.61 322.93
Government spending (% of GDP) 135 17.15 11.27 3.68 101.75
Civil liberties (Freedom House Index) 135 3.72 1.68 1.00 7.00
Internet (% population with internet access) 135 18.05 15.60 0.47 56.44
Share of population with at least secondary education 135 47.94 25.71 0.00 95.73
Share of population reporting they trust other (WVS) 135 24.26 15.02 3.50 73.90
Trust information missing 135 0.32 0.47 0.00 1.00
Proportion area in polar zone 135 0.02 0.06 0.00 0.30
Proportion area in boreal zone 135 0.06 0.16 0.00 0.91
Proportion area in dry temperate zone 135 0.04 0.13 0.00 0.95
Proportion area in wet temperate zone 135 0.20 0.32 0.00 1.00
Proportion area in subtropical zone 135 0.29 0.33 0.00 0.98
Proportion area in tropical zone 135 0.17 0.26 0.00 1.00
https://doi.org/10.1371/journal.pone.0251424.t001
PLOS ONE Mortality, morbidity and economic growth
PLOSONE | https://doi.org/10.1371/journal.pone.0251424 May 27, 2021 6 / 22
per-capita GDP growth (over the period between 1990 and 2014, the last year for which all the
information is available) to initial income and, alternately, the average mortality rate and the
average DALY over the same period. Formally the model is specified as follows:




is the long run growth rate of real per-capita GDP in country i from 1990
to 2014, log(yi1990) is the logarithm of per-capita GDP in 1990, the initial condition, pop65i1990
is the share of the population aged 65 and more in 1990, that we interpret as an indicator or
the stage of the demographic transition at the beginning of the period, �Ri is respectively the
average mortality or DALY between 1990 and 2014, �X i is a vector of time-varying country con-
trols averaged over the period 1990–2004 andWi a vector of time-invariant controls.
Time-varying controls include log population, proportion of urban residents, proportion of
residents with internet access, government spending, and an index of openness to the global
economy (defined as the ratio between the sum of imports and exports and national GDP),
human capital (proxied by the share of population with at least secondary education) and
social capital (the share of population reporting that their trust the others in the WVS). Time-
invariant controls include a set of variables accounting for the proportion of the country area
in polar, boreal, humid temperate, dry temperate, subtropical and tropical zones, and two
proxies of institutional quality (an index of civil liberties and the condition of being a member
of the OECD in 1990).
Error terms of neighboring countries may be correlated. As a robustness check we estimate
the same regression by clustering the standard error at the macro-regional level (i.e., East Asia
& Pacific, Europe & Central Asia, Latin America & Caribbean, Middle East & North Africa,
North America, South Asia, Sub-Saharan Africa) to account for possible correlation of the
error terms within macro-regions, due to the interlinked economic dynamic of neighboring
countries. Due to the limited number of clusters, we bootstrap the standard errors using wild
bootstrap.
The key explanatory variable is �Ri and the parameter of interest is its marginal effect π2.
Variable �Ri is likely endogenous for three reasons. First, �Ri can be correlated with unobservable
country characteristics omitted from the model. Particularly, the usual catching-up of the less
developed towards the more developed economies is only partially accounted for by the inclu-
sion of initial income in 1990 in a long run model that spans over two decades. Second, �Ri
could suffer from measurement error [1]. Third �R i could suffer from reverse causation,
because during periods of economic growth social interactions and the spread of viruses and
communicable diseases increase [24], lifestyles change, housing and working conditions
improve, access to healthcare services expands, although stress and road traffic injuries escalate
(see [25] and [3], for an ampler account).
To address endogeneity, we use three complementary strategies. First, we acknowledge that
we may fail to account for some unobservables. Following [10], we compute the size of the
coefficient we would get if the selection on unobservable was accounted for. As in [10], we
assume that unobservables are as important as observables in explaining long run growth, and
that their introduction improves model explanatory power (i.e. the R2) by respectively 30 per-
cent and 50 percent. Under these conditions we estimate the resulting parameter π2. Our esti-
mates indicate that the correlation between �Ri and ε is positive and the OLS estimates are
upward biased (i.e. they are negative, but smaller in absolute value, compared to the plausibly
unbiased estimates). In other words, the selection bias makes the effect estimated by OLS
conservative.
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Second, we adopt an instrumental variables (IV) strategy to put under scrutiny the finding
that OLS estimates are conservative. While LMW instrument �R i by the Malaria Ecology Index
(a measure of predicted mortality due to malaria in 2004 defined by [17]) and a series of cli-
matic and geographic characteristics, we opt for a just identified two-stages least squares esti-
mator (2SLS). �R i is instrumented with the Malaria Falciparum Index prevailing in 1966 (Z),
i.e. the proportion of the population of 1966 exposed to Plasmodium Falciparum, the most
prevalent type of malaria, especially in Africa. We believe that the 1966 Malaria Falciparum
Index is preferable over the Malaria Ecology Index because it is based on data referring to a
time largely preceding our study period and does not depend on the malaria protection poli-
cies implemented by the countries in the recent decades.
Differently from LMW, we add the proportions of the country surface belonging to the
Köppen-Geiger climatic zones to the controls, instead of including them in the set of instru-
ments. We take this stand for two main reasons. First, climatic zones may have a direct effect
on GDP growth, because they shape agricultural productivity and likely contribute to set the
path of long run economic development. Second, overidentified models with many instru-
ments tend to exacerbate the finite sample bias of IV estimators, unless all instruments are
strong enough to keep high the first stage F statistics ([26], p.209). Unfortunately, this is not
the case with LMW instruments, as it is evident from their first stage results (Tab 6 in LMW).
In our analysis identification depends on the variation of the Malaria Falciparum Index for
given distribution of climatic zones in a country. Such variation is ample because in most
countries we observe a plurality of climatic zones. Only two countries of the sample belong to
a unique climatic zone, and only in 24 cases out of 135, one climatic zone covers more than 90
percent of the surface. Moreover, while the prevalence of malaria is high in tropical and sub-
tropical areas, not all countries which are prevalently tropical and subtropical are equally
affected by malaria, the spread of which depends on land elevation, humidity, presence of
water pools and the effectiveness of past eradication campaign. Similarly, while malaria is less
prevalent temperate areas, about one third of the countries mainly located in temperate
regions were affected by malaria, to different extents, in 1966.
An instrumental variable is valid if it satisfies the conditions of relevance (i.e., the instru-
ment is correlated with mortality/morbidity) and excludability (i.e., the instrument does not
directly affect GDP growth). The first requirement is testable, and we show that our instru-
ment is strongly correlated with mortality and DALYs. The excludability condition is untest-
able, at least in a just identified model. We are concerned that the instrument may affect GDP
growth via its correlation with other country characteristics. First, malaria prevalence may be
correlated with climate features that can directly affect growth: to partly neutralize this channel
we condition on climatic zones. Second, malaria prevalence may be high in Sub-Saharan
Africa, a region that historically had low economic growth due to poor institutions and a
recent past of colonial domination [5]. To address this concern, we condition on measures of
institutional quality such as the index of civil liberties (derived from the Freedom House), the
status of member of the OECD in 1990 and internet diffusion as a proxy of access to informa-
tion. We acknowledge, however, that despite these controls, malaria can have influenced the
process of economic development through alternative mechanisms, including the kind of pro-
ductive specialization and the level of transportation and transaction costs.
For these reasons we apply two methods of partial identification proposed by [12] and [13]
and we use generated heteroskedasticity-based instruments proposed by [14]. [12] and [13] derive
bounds for the coefficients for small deviations from the excludability condition i.e., if we assume
that the instrument has a (small) direct effect on GDP growth; [14] suggests alternative instru-
ments that can help identification as they meet the excludability condition by construction.
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Following [12] we compute what is the largest direct effect compatible with a statistically
significant effect of mortality on economic growth. [12] suggests two methods to achieve this
purpose. The first assumes a plausible range of variation for the direct effect. For each value of
the direct effect, we can compute a different value of the marginal effect π2. The confidence
intervals of π2 are computed as the union of the confidence intervals obtained for each possible
value taken by the direct effect (union of confidence interval approach). The second method
assumes that the coefficient of the direct effect is a random variable with a probability distribu-
tion (local to zero approach). Explicit bounds can be obtained under the assumption that the
direct effect follows a Gamma distribution.
[13] shows that it is possible to obtain informative bounds on the true value of π2 even if the
instrument has a direct effect on the GDP growth, provided that the sign of the correlation
between the endogenous variable �R i and the error term ε is the same as the sign of the correla-
tion between the instrument Z and error term ε. We have mentioned above that the correla-
tion between �Ri and ε is positive. We suggest that also the correlation between exposure to
malaria falciparum (Z) and ε is positive. [13] shows that if the correlation between �Ri and ε
has the same sign as the correlation between Z and ε, then π2<min[π2
IV, π2
OLS].
[14] proposes an approach to generate additional instruments to use in combination with
Z. Such instruments are created using a subset V of the controls in (1) i.e., a subset of the vector
[�X ,W]. For each variable in V, we can construct a new instrument ZL = (V–E(V))θ where θ is
the error term of the regression of �Ri on �X and W, and E(V) is the average of V in the sample.
Under exogeneity of the controls in V and heteroscedasticity of ε, the generated instruments
ZL are correlated with �R i and uncorrelated with ε. Therefore, they met the excludability condi-
tion and are valid. Adding the generated instruments to Z makes the model overidentified and
allows to perform an overidentification test to assess Z validity. We adopt this procedure in
two polar manners. First, to keep the IV finite sample small, we add only one strong generated
instrument [26]. Hence, we specify V as the percentage of the country in tropical or subtropical
areas, which is strongly correlated with �R i. Second, to avoid any arbitrariness in the specifica-
tion, we make V coinciding with the full set of controls, i.e. V = [�X ,W]. This maximizes the
number of overidentifying restrictions, but the IV finite sample bias is expected to be large in
this case, despite all additional instruments are exogenous by construction.
5. Results
Baseline results are reported in Table 2 (and fully displayed in Table A1). The upper panel
refers to mortality and the lower panel to DALYs. In column 1 we report OLS estimates of Eq
(1). Clustering the standard errors at the regional level, to account for possible interdepen-
dences between countries performances, makes the estimates only marginally less precise (see
Table A2). Following [10], we investigate the bias due to possible unobservables, under the
assumption that unobservables and observables are equally correlated with mortality (resp.
DALY). This assumption corresponds to a conservative scenario according to [27] and [10].
We observe that removing the selection bias increases (in absolute value), rather than offset-
ting, the estimated effect of mortality and DALYs on economic growth, which would fade out
only under the implausible assumption that included controls and omitted variables are corre-
lated with mortality/morbidity in opposite ways. Assuming that the inclusion of unobservables
increases model explanatory power by, respectively 30 percent (column 2 of Table 2) and by 50
percent (column 3), we find that the bunding sets for the effect of population mortality on eco-
nomic growth, expressed as semi-elasticities, are respectively [-1.048,-0.802] and [-1.317,-
0.802]. Reassuringly, these bounding sets are rather narrow and reveal that reducing mortality
by 10 percent increases the long run economic growth by between 8 and 13 percentage points.
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The corresponding bounding sets for the effect of DALY on economic growth are about half
as large: reducing DALYs per capita of 10 percent adds between 4.9 and 6.4 percentage points
to the long run economic growth. We judge the size of these effects as moderate if compared
with the GDP per-capita growth rate of US (41.23 percent), China (441.96 percent), India
(207.2 percent) and Niger (7.06 percent), in the period.
Comparing column 1 with either columns 2 or 3, we conclude that OLS estimates are
upward biased (less negative than they should be), implying that the correlation between �Ri
and the error term ε is positive. Hence mortality and morbidity are higher in countries that
have a larger potential for growth unexplained by the controls in model (1). We conjecture
that part of this positive correlation can be attributed by the usual catching-up effect. A similar
result was detected in LMW and was ascribed to measurement errors by the authors.
IV estimates support the conclusions of the test proposed in [10] and confirm that OLS esti-
mates are conservative (see Table 3). Indeed, IV estimates are twice as large in absolute value
than OLS for DALYs, and are marginally larger for mortality. The gap between OLS and IV
estimates in the case of DALYs may signal that the OLS is underestimated because of reverse
causation. Indeed, morbidity increases during economic expansion due to the spread of com-
municable diseases, increased stress, and road traffic accidents, which might hamper labour
supply and productivity, without impacting mortality appreciably (see [24]). The Kleibergen-
Paap rank test displays a F statistic of 58.066 and 24.535 in the case of mortality and DALY
respectively, providing evidence that our instrument is strong.
IV estimates could be inflated if malaria affected economic activity not only indirectly,
through increased mortality and morbidity, but also directly by hampering economic activi-
ties. We scrutinize the stability of our IV estimates by relaxing the assumption of exogeneity of
the instrument. We start by considering Conley’s test [12]. Results are reported in Fig 1A for
mortality rates and 1B for DALYs. In all cases we report the 90-percent confidence intervals
associated to π2 under various hypothesis regarding the distribution of γ, i.e. the direct effect of
Z on gi. In the first panel, we adopt the union of confidence intervals method, and set γ
between -40 and +40. In the second panel and third panel we assume that γ follows a Gamma
Table 2. The effect of mortality/DALYs on GDPpc growth. Long-Run Growth Regression.
(1) OLS (2) Oster’s (2019) estimate (Rmax = 1.3� R2) (3) Oster’s (2019) estimate (Rmax = 1.5� R2)
All-Cause mortality rate (per 100,000 inhabitants) -0.090��� -0.117 -0.147
(0.022)
Semi-elasticity -0.802 -1.048 -1.317
R2 / Rmax 0.498 0.647 0.747
All-Cause DALYs (x 100 inhab.) -2.648 �� -3.069 -3.412
(1.017)
Semi-elasticity -0.493 -0.572 -0.636
R2 / Rmax 0.448 0.582 0.672
Observations 135 135 135
Note: Robust standard errors in parentheses.
��� p<0.01,
�� p<0.05,
� p<0.1. Controls are: Log real GDP per capita 1990, share of the population aged 65 and over in 1990, OECD 1990, log population, dummy indicator of rural areas,
government spending, civil liberty index, percentage of household with internet access, share of population with at least secondary education, share of population
reporting their trust the others in the WVS, dummy indicating whether the trust variable has been imputed, % of country area in polar zone, % of country area in boreal
zone, % of country area in temperate zone, % of country area in subtropical zone, % of country area in tropical zone. Semi-elasticity is defined as the effect on economic
growth (measured as percentage points) of reducing mortality by 1 percent at the sample mean.
https://doi.org/10.1371/journal.pone.0251424.t002
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distribution with respectively mean μ between -40 and +40 and variance equal to μ2. Results
indicate that π2 would be statistically insignificant if the direct effect γ was (approximately)
smaller (more negative) than -15. We consider this case unlikely because it would imply that γ
would be larger than one fourth of the value of the total effect of Z in the reduced form equa-
tion (i.e., -52.46), which accounts for both the direct effect of Z and that mediated by the
endogenous variable. For any value of γ> -15, our conclusions on the size of the real causal
effect π2 would be either qualitatively confirmed or reinforced.
When the instrument exclusion restriction is violated, [13] show that the true causal effect
π2must be smaller than both the IV and the OLS estimates, that is π2<min[π2
IV, π2
OLS], if the
correlation between the �Ri and the error term ε has the same sign as the correlation between
the instrument Z and the error term ε. Since π2
IV
< π2
OLS (Table 2), corr (�Ri, ε) must be posi-
tive. We show that corr(Z, ε) is also positive by means of a two-stage Oster’s test [10]. More
specifically, we apply the method in [10] separately on the reduced form and the first stage cor-
responding to model (1) and assess how unobservables influence a) the correlation between Z
and gi, and b) the correlation between Z and �R i. It turns out that the inclusion of unobservables
slightly increases in absolute value the reduced form coefficient while it largely shrinks the
coefficient of first stages, preserving their sing (Table 3). Therefore, accounting for unobserva-
bles produces even more negative IV estimates (recalling that the IV estimate is the ratio
between the reduced form and the first stage parameters in a just identified model) and implies
that corr(Z,ε)>0. We conclude that the true causal effects are bounded from above by our IV
estimates, and they satisfy π2<-0.096 for mortality (semi-elasticity<-0.861), and π2<-5.686
for DALYs (semi-elasticity<-1.060).
Table 3. The effect of mortality/DALYs on GDPpc growth. Reduced form and first stage.
(1) IV (1) OLS: reduced
form
(2) Oster’s (2019) estimate
(Rmax = 1.3� R2) Reduced form
(3) OLS: First
stage
(4) Oster’s (2019) estimate
(Rmax = 1.3� R2) First stage
All-Cause mortality rate (per 100,000
inhabitants)
-0.096 ��� -52.462�� -56.669 545.979 ��� 357.4535
(0.037) (22.592) (72.591)
Semi-elasticity -0.861
R2 / Rmax - 0.4340 0.5714 0.6953 0.9039
First stage Kleibergen-Paap F test on
excluded instruments
58.07
All-Cause DALYs (x 100 inhab.) -5.687 �� -52.462�� -56.669 9.225��� 6.28446
(2.488) (22.592) (1.866)
Semi-elasticity -1.060
R2 / Rmax - 0.4340 0.5714 0.5012 0.6516
First stage Kleibergen-Paap F test on
excluded instruments
24.535
Observations 135 135 135 135 135
Note: Robust standard errors in parentheses.
��� p<0.01,
�� p<0.05,
� p<0.1. Controls are: Log real GDP per capita 1990, share of the population aged 65 and over in 1990, OECD 1990, log population, dummy indicator of rural areas,
government spending, civil liberty index, percentage of household with internet access, share of population with at least secondary education, share of population
reporting their trust the others in the WVS, dummy indicating whether the trust variable has been imputed, % of country area in polar zone, % of country area in boreal
zone, % of country area in temperate zone, % of country area in subtropical zone, % of country area in tropical zone. Semi-elasticity is defined as the effect on economic
growth (measured as percentage points) of reducing mortality by 1 percent at the sample mean.
https://doi.org/10.1371/journal.pone.0251424.t003
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To further assess the robustness of our IV estimates, we add to our model the Lewbel’s gen-
erated instruments [14] in combination with Z. We start with the most parsimonious specifi-
cation where we add only one generated instrument, the one derived from the proportion of
county located in the tropical and subtropical climatic regions. We test instrument relevance,
and we find that instruments are strong, as the Kleibergen-Paap rank test yields an F statistic
of 45.87 (resp. 18.38) in the mortality (resp. DALY) first-stage regression. The Hansen over-
identification test displays a J statistic of 0.372 (p = 0.5419) in the model of mortality, and
0.320 (p = 0.5719) in that of DALYs and does not reject the null hypothesis of instrument’s
exogeneity. The coefficients π2 in both regressions (column 3 of Table 4) are close to those
obtained via our baseline IV specification (column 2) and are statistically significant at conven-
tional levels. With the richest specification, where we add as many instruments as are our con-
trols in model (1), the F statistics of Kleibergen-Paap rank test turn to be lower, especially so
for DALYs, indicating that some of those instruments are weak (F = 18.735 for mortality and
F = 10.349 for DALYs). The Hansen J statistic are 21.289 (p = 0.2651), for mortality and 25.485
Fig 1. A. Small violations of the exogeneity assumption on the effect of mortality (Conley et al. 2012). B. Small violations of the exogeneity assumption on the
effect of DALY (Conley et al. 2012). Note: upper panel: union of confidence interval approach; middle panel: local to zero approach with variance equal to the
square of the mean; lower panel: local to zero approach with variance equal to the mean. π2 is the real causal effect of mortality on GPD per capita growth and γ
is the direct effect of the instrument on GDP per capita growth.
https://doi.org/10.1371/journal.pone.0251424.g001
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(p = 0.1121) for DALYs. Point estimates remain stable for mortality and get smaller for
DALYs. As to be expected with many weak instruments [26], the latter estimates are likely
biased towards the OLS.
We finally investigate possible heterogeneous effects by distinguishing between countries
classified as low, lower-middle, upper-middle and high income according to the World Bank
income group classification as of 2014. We add to model (1) the interaction between �R i and
four dummies, each indicating one class of countries. We also study how effects vary with the
share of population aged 65 and above in 1990, an indicator of the stage of demographic transi-
tion at the beginning of the period. We cut this variable in three intervals, below 5 percent,
between 5 and 10 percent and above 10 percent. We group countries accordingly, and each
group corresponds to a dummy variable that we interact with �Ri. Most countries cluster in the
first interval and among them there is little variation in the share of the senior population. The
remaining countries are evenly distributed across the two remaining intervals. We remark that
there is not perfect overlapping among the country grouping by income and by share of the
senior population. Among countries where the share of the senior population is less than 5
percent, we find most low income countries besides several rich and middle income countries
in the Gulf area and Eastern Asia. Viceversa, among the countries with large shares of senior
population we find most high income countries, but also Belarus, Russia, and other middle
income countries in Eastern Europe and Central Asian.
Including interactions of �R i with indicators of country groups makes model specifications flex-
ible and avoids assuming any functional form for the pattern of effects across countries. Leverag-
ing on the previous analysis, which points out that OLS estimates are, if anything, conservative,
and given the larger precision of OLS compared to the IV estimator, the heterogeneity analysis is
conducted by OLS. Results are reported in Figs 2 and 3 and Tables A3 and A4 in appendix.
In both cases we do observe non linear patterns. The effects of mortality and morbidity
tend to be stronger in the poorest and the richest countries than in the middle-income coun-
tries. Moreover, the effect vanishes in the countries with a proportion of senior population
larger than 10 percent. These results imply that reducing mortality is more beneficial in coun-
tries at an earlier stage of demographic transition, supporting the mechanism proposed by [6],
but also in those rich countries whose population is relatively older, but enjoys high levels of
human capital, which in turn supports seniors’ labour productivity.
Table 4. The effect of mortality/DALYs on GDPpc growth. Long-Run Growth Regression estimated adding Lewbel’s (2012) heteroskedasticity based instruments.
OLS IV IV Lewbel (2012) (V = country area in the tropical and
subtropical region)
IV Lewbel (2012) (V = all
controls)






- 0.089 ��� (0.031) -0.094��� (0.028)
Semi-elasticity -0.802 -0.861 -0.795 -0.841




-4.820�� (2.145) -2.639� (1.351)
Semi-elasticity -0.493 -1.060 -0.898 -0.492
Note: Robust standard errors in parentheses.
��� p<0.01,
�� p<0.05,
� p<0.1. Controls are: Log real GDP per capita 1990, share of the population aged 65 and over in 1990, OECD 1990, log population, dummy indicator of rural areas,
government spending, civil liberty index, percentage of household with internet access, share of population with at least secondary education, share of population
reporting their trust the others in the WVS, dummy indicating whether the trust variable has been imputed, % of country area in polar zone, % of country area in boreal
zone, % of country area in temperate zone, % of country area in subtropical zone, % of country area in tropical zone.
https://doi.org/10.1371/journal.pone.0251424.t004
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6. Themacroeconomic effects of investing to reducemortality and
morbidity
To illustrate the relevance and magnitude of our findings, we compute the net present value of the
flow of differential income per capita generated as a result of a marginal reduction (resp. increase)
in mortality and morbidity. This back-of-the-envelope calculation might help governments
Fig 2. Heterogeneous effects byWB classification group.Note: Average treatment effects by WB classification
group. Average treatment effects for the full sample (dotted line).
https://doi.org/10.1371/journal.pone.0251424.g002
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evaluate the macroeconomic benefit (resp. costs) of investment decisions in health policies effec-
tive in reducing mortality andmorbidity. The macroeconomic payoff of improving population
health adds to the human and welfare benefits that have been discussed for instance by [28].
We consider four countries as case studies. We chose one country for each category of the
2014World Bank income group classification: the US (high income), China (upper-middle
Fig 3. Heterogeneous effects byWB percentage of people over 65 in 1990.Note: Average treatment effects for
countries whose percentage of people over 65 in 1990 is below 5% (group 1), above or equal 5% and below 10% (group
2), and 10% or more (group 3),. Average treatment effects for the full sample (dotted line).
https://doi.org/10.1371/journal.pone.0251424.g003
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income), India (lower-middle income) and Niger (low income). Perhaps optimistically, we
assume that these four countries will be able to replicate the same reduction in mortality rates
and DALYs in future periods (i.e. the period between 2015 and 2039), which they experienced
in the previous quarter century (1990–2014). Between 1990 and 2014, the change in mortality
(DALY) was -5.3 percent (+1.39 percent) in the US, -23.43 percent (-8.91 percent) in China,
-23.74 percent (-9.88 percent) in India, and -9.67 percent (-12.1 percent) in Niger. Since we
interpret the replication of these dynamics as the result of mere continuation of past health
policies, we name this the status quo scenario.
We consider two alternative scenarios, the positive action scenario, and the negative action
scenario which assume that countries step up (resp. step down) their health policy efforts and
hence achieve an additional reduction (resp. increase) in mortality and DALYs by 1 percentage
point, compared to the status quo. For instance, the US will experience a reduction in mortal-
ity of 6.3 percent in the positive action scenario and a reduction of 4.3 percent in the negative
action scenario, compared to the 5.3 percent in the status quo scenario while, in Niger, the fall
in DALYs will be 13.1 percent in the positive action scenario and 11.1 in the negative action
scenario, rather than 12.1 percent in the status quo.
We compute the economic benefit of such actions by comparing the dynamics of GDP per
capita between 2014 and 2039 under the status quo and the two action scenarios, predicted on
the basis of our (conservative) OLS estimates. We assign to each country the estimate corre-
sponding to its income category, as reported in Table A3. Fig 4 reports the differential GDP
per capita accruing under the actions scenario by year and country, while Table 5 reports the
net present value (applying a 2 percent yearly discount rate) of the action scenarios, and how
such figures compare with GDP per capita in 2014. The effect of the positive and negative
action scenarios are practically symmetric. Larger benefits are experienced by Niger and USA,
Fig 4. Differential GDP per capita under the action scenario compared to the status quo between 2015 and 2039.
By year and country. Note: left panel: mortality; right panel: DALY. Positive action scenario in gray and negative action
scenario in black.
https://doi.org/10.1371/journal.pone.0251424.g004
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given the stronger effect of mortality and morbidity on long run growth. The differential
(macro)economic value of the action scenarios compared to the status quo is 5.1 percent of
2014 GDP per capita in Niger and 10 percent in the US. Turning to DALYs, the value of the
action scenarios is respectively 4.8 and 6.1 percent of 2014 GDP per capita in Niger and the US
respectively. These figures would be proportionally larger if the action scenarios diverged of
more than one percentage point from the status quo. Especially as regards mortality, we judge
the differential economic payoff of the action scenarios as moderate but non-negligible.
7. Conclusion
We have thoroughly reconsidered the role of mortality and morbidity as determinants of eco-
nomic growth, thereby contributing to a long-standing debate that had been fueled by influen-
tial studies reaching contrasting results. Our approach is close to LMW but it extends the
analysis in three respects. First, it uses more recent and internationally comparable data on
mortality and DALYs, the latter being a composite measure of mortality and morbidity that, to
the best of our knowledge, has not previously been considered in the health and growth litera-
ture. Second, the sample of countries is much larger than in past studies and, third, acknowl-
edging the difficulties of the empirical analysis, we provide bounding sets for the effects of
interest rather than point estimates.
We find that reducing mortality and morbidity is beneficial to long run economic growth.
Specifically, reducing mortality (resp. DALYs) by 10 percent increases the growth in GDP per
capita over a quarter century by at least 9.6 (resp. 10.6) percentage points on average (upper
bound derived according to the Nevo-Rosen procedure). Conley’s and Lewbel strategies sug-
gest that our IV estimates are robust to violations of the exclusion restriction.
We also find that the effects are rather heterogenous and they are driven by low income and
high-income countries, among which the effect is higher in absolute value than that in middle
income countries, for both mortality and DALYs (See Table A3). Similarly, we find non-linear
patterns across countries depending on the stage of the demographic transition they are in at
the beginning of the study period. Generally, the effects are smaller in absolute terms in coun-
tries where the share of the senior population exceeds 10 percent.
Finally, we use our findings to estimate the net present value of investing more or less
resources on health policies to accelerate (resp. slow down) mortality and morbidity declines
Table 5. GDP per capita gains due to a decrease/increase in mortality (morbidity) between 2015 and 2039 1 p.p. bigger than that between 1990 and 2014.
Mortality: Net present value of the
positive action scenario
Mortality (positive action): % of
the 2014 GDP
Mortality: Net present value of the
negative action scenario
Mortality (negative action): % of
the 2014 GDP
Niger 45.6 5.1 -45.6 -5.2
India 167.8 3.0 -167.9 -3.0
China 244.3 2.0 -244.4 -2.0
USA 5140.4 10.0 -5151.4 -10.0
Morbidity: Net present value of the
positive action scenario
Morbidity (positive action): % of
the 2014 GDP
Morbidity: Net present value of the
negative action scenario
Morbidity (negative action): % of
the 2014 GDP
Niger 42.7 4.8 -42.7 -4.8
India 142.0 2.6 -142.0 -2.6
China 34.7 0.3 -34.7 -0.3
USA 3173.5 6.1 -3177.9 -6.2
Note: Net present value of the additional flow of income per capita accruing under the action scenario, compared to the status quo scenario, between 2014 and 2039.
Projections based on the estimates reported in Table 4. Yearly discount rate: 2 percent.
https://doi.org/10.1371/journal.pone.0251424.t005
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in four representative countries, the US, China, India and Niger. We compute the (macro)eco-
nomic benefit (resp. costs) under two hypothetical action scenarios, where the long run change
in mortality and DALYs are increased (resp. reduced) by 1 percentage point during the period
2015–2039 compared to a status quo scenario. For mortality, the economic benefit of the posi-
tive action scenario and the economic cost of the negative action scenario are practically sym-
metric and turn out to be higher in the US and Niger (10 percent and 5.1 percent of their 2014
per-capita GDP) and lower in China and India (2 percent and 0.3 percent of the 2014 per cap-
ita GDP respectively). Figures for DALY are smaller, but they reflect the use of more conserva-
tive estimates of the effect of morbidity on economic growth. These figures suggest that the
economic growth payoff from investments to improve health could be an additional factor to
consider in the cost-benefit analyses of large-scale, population-level health policies.
Appendix: Additional tables
Table A1. The effect of mortality and DALY on GDPpc growth. Long-Run Growth Regression (full specification reported).
OLS IV OLS IV
All-Cause mortality rate (per 100,000 inhabitants) -0.090��� -0.096���
(0.019) (0.037)
All-Cause DALY (per 100 inhabitants) -2.648��� -5.687��
(0.873) (2.488)
Log real GDPpc 1990 -43.181��� -43.717��� -34.436��� -32.783���
(11.079) (10.314) (10.223) (9.668)
OECD 1990 -46.974�� -47.833�� -40.492� -46.509��
(20.938) (19.191) (21.861) (20.731)
Log population 19.837��� 19.608��� 21.676��� 20.207���
(4.379) (5.320) (4.556) (5.591)
Urban -0.569 -0.594 -0.432 -0.661
(0.368) (0.471) (0.384) (0.514)
Openness 0.517��� 0.514��� 0.569��� 0.583���
(0.142) (0.120) (0.149) (0.135)
Government spending -1.528��� -1.519��� -1.616��� -1.576���
(0.410) (0.224) (0.429) (0.291)
Civil liberties -5.150 -4.998 -7.145 -7.043
(4.209) (4.413) (4.388) (4.797)
Internet 1.337� 1.275� 1.552� 0.824
(0.784) (0.707) (0.826) (0.880)
% area in polar zone -108.569 -109.373 -105.286 -114.112
(110.799) (104.593) (116.170) (125.825)
% area in boreal zone 89.851� 91.663��� 86.926� 111.945���
(46.388) (32.436) (48.846) (40.799)
% area in dry temperate zone 59.380� 61.097� 61.632� 91.109�
(33.323) (31.982) (35.557) (46.869)
% area in wet temperate zone 55.570� 57.603� 48.644 72.543��
(30.107) (29.485) (31.689) (35.738)
% area in subtropical zone 38.709� 40.223� 42.568� 70.702��
(22.649) (21.213) (24.647) (33.327)
% area in tropical zone -10.743 -9.265 -23.852 -15.748
(Continued)
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Table A1. (Continued)
OLS IV OLS IV
(26.028) (21.543) (27.007) (23.127)
Population older than 65 2.442 2.901 -3.735 -3.644
(3.106) (3.661) (2.934) (2.627)
Share of population with secondary education 0.227 0.226 0.314 0.393
(0.325) (0.302) (0.342) (0.374)
Share of population who trust other 0.634 0.658 0.579 0.890
(0.530) (0.657) (0.558) (0.722)
Missing trust 19.766 20.421 16.684 23.412
(14.594) (20.789) (15.290) (22.261)
Constant 141.961 153.517 36.864 97.217
(109.250) (96.037) (110.234) (102.057)
Semi-elasticity -0.802 -0.861 -0.493 -1.060
R2 0.498 0.448
F 58.07 24.535
Observations 135 135 135 135
Note: Robust standard errors in parentheses.
��� p<0.01,
�� p<0.05,
� p<0.1. Semi-elasticity is defined as the effect on economic growth (measured as percentage points) of reducing mortality by 1 percent.
Table A2. The effect of mortality/DALYs on GDPpc growth. Long-Run Growth Regression (standard errors clus-
tered at the regional level and bootstrapped using wild bootstrapping).
(1) OLS (s.e clustered at the regional level)









Note: Wild bootstrapped cluster-robust standard errors in parentheses.
��� p<0.01,
�� p<0.05,
� p<0.1. Controls as in Table A1. Semi-elasticity is defined as the effect on economic growth (measured as percentage
points) of reducing mortality by 1 percent.
Table A3. The effect of mortality/DALYs on GDPpc growth. Long-Run Growth Regression. Effects by World Bank Country Income Group. OLS.
Low GDP countries Middle Low GDP countries Middle High GDP countries High GDP countries
All-Cause mortality rate (per 100,000 inhabitants) -0.114��� -0.056�� -0.035 -0.137 ���
(0.038) (0.026) (0.030) (0.034)
Semi-elasticity -1.020 -0.501 -0.316 -1.227
R2 0.6671 0.6671 0.6671 0.6671
(Continued)
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Table A3. (Continued)
Low GDP countries Middle Low GDP countries Middle High GDP countries High GDP countries
All-Cause DALYs (x 100 inhab.) -3.567��� -2.054� -0.241 -3.874���
(1.268) (1.119) (1.245) (1.418)
Semi-elasticity -0.665 -0.382 -0.045 -0.722
R2 0.6248 0.6248 0.6248 0.6248
Observations 135 135 135 135
Note: Robust standard errors in parentheses.
��� p<0.01,
�� p<0.05,
� p<0.1. Controls are: Log real GDP per capita 1990, share of the population aged 65 and over in 1990, OECD 1990, log population, dummy indicator of rural areas,
government spending, civil liberty index, percentage of household with internet access, share of population with at least secondary education, share of population
reporting their trust the others in the WVS, dummy indicating whether the trust variable has been imputed, % of country area in polar zone, % of country area in boreal
zone, % of country area in temperate zone, % of country area in subtropical zone, % of country area in tropical zone. Semi-elasticity is defined as the effect on economic
growth (measured as percentage points) of reducing mortality by 1 percent at the sample mean.
Table A4. The effect of mortality/DALYs on GDPpc growth. Long-Run Growth Regression. Effects by Percentage of people over 65. OLS.
Percentage of people above 65 smaller
than 5%
Percentage of people above 65 between
5% and 10%
Percentage of people above 65 bigger
than 10%




Semi-elasticity -0.699 -1.466 -0.283
R2 0.5417 0.5417 0.5417
All-Cause DALYs (x 100 inhab.) -2.112�� -4.067 -0.064
(1.055) (3.089) (2.584)
Semi-elasticiy -0.394 -0.758 -0.012
R2 0.4906 0.4906 0.4906
Observations 135 135 135
Note: Robust standard errors in parentheses.
��� p<0.01,
�� p<0.05,
� p<0.1. Controls are: Log real GDP per capita 1990, share of the population aged 65 and over in 1990 (3 dummies), OECD 1990, log population, dummy indicator of
rural areas, government spending, civil liberty index, percentage of household with internet access, share of population with at least secondary education, share of
population reporting their trust the others in the WVS, dummy indicating whether the trust variable has been imputed, % of country area in polar zone, % of country
area in boreal zone, % of country area in temperate zone, % of country area in subtropical zone, % of country area in tropical zone. Semi-elasticity is defined as the effect
on economic growth (measured as percentage points) of reducing mortality by 1 percent at the sample mean.
Table A5. The effect of mortality/DALYs on GDPpc growth. Long-Run Growth Regression. Effects by alternative measures of mortality and morbidity.
OLS IV OLS IV
All-Cause mortality rate (per 100,000 inhabitants), age 15–64 -0.078��� -0.132��
(0.027) (0.055)
All-Cause DALY (per 100 inhabitants), all ages -1.579��� -1.501���
(0.342) (0.551)
Observations 135 135 135 135
(Continued)
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